Table 2.

Association between TML and time-to-first treatment among individuals with HCMBL

CLL-IPI	Mutated genes	Total		Event	HR	95% CI	P value
		N	col %	N
Overall∗	None	147	51.0	9	1.00	Reference
(N = 288)	Any	141	49.0	48	5.37	(2.63-10.98)	<.0001
	0	147	51.0	9	1.00	Reference
	1	90	31.3	31	5.30	(2.51-11.21)	<.0001
	≥2	51	17.7	17	5.50	(2.44-12.36)	<.0001
	Cont.	288	100	56	1.59	(1.33-1.89)	<.0001
	c-statistic	0.726				(0.65-0.80)
Low-risk CLL-IPI†	None	103	57.5	5	1.00	Reference
(n = 179)	Any	76	42.5	18	4.30	(1.57-11.79)	.005
	0	103	57.5	5	1.00	Reference
	1	56	31.3	14	4.47	(1.56-12.77)	.005
	≥2	20	11.2	4	3.88	(1.04-14.47)	.043
	Cont.	179	100	23	1.75	(1.15-2.68)	.009
	c-statistic	0.660				(0.56-0.76)
Intermediate-risk CLL-IPI†	None	27	38.6	4	1.00	Reference
(n = 70)	Any	43	61.4	20	3.04	(1.02-9.01)	.045
	0	27	38.6	4	1.00	Reference
	1	23	32.9	11	3.51	(1.11-11.14)	.033
	≥2	20	28.6	9	2.57	(0.77-8.55)	.123
	Cont.	70	100	24	1.48	(1.04-2.11)	.028
	c-statistic	0.650				(0.54-0.76)
High- to very high–risk CLL-IPI†	None	24	52.2	0	1.00	Reference
(n = 46)	Any	22	57.8	9	NA	NA	NA
	0	24	52.2	0	1.00	Reference
	1	11	23.9	5	NA	NA	NA
	≥2	11	23.9	4	NA	NA	NA
	Cont.	46	100	9	1.48	(1.07-2.07)	.019
	c-statistic	0.803				(0.71-0.90)

col, column; Cont., continuous; NA, not applicable.

^∗Adjusted for CLL-IPI and sex.

^†Adjusted for sex.